Literature DB >> 23207285

Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: a systematic review and meta-analysis.

Antonio-Javier Chamorro1, Miguel Marcos, Ignacio Hernández-García, Antonia Calvo, Juan-Carlos Mejia, Ricard Cervera, Gerard Espinosa.   

Abstract

UNLABELLED: Thrombosis is frequent in patients with Behçet's disease (BD), although the exact cause remains uncertain. Some single nucleotide polymorphism (SNP) (G1691A in factor V gene, also called factor V Leiden [FVL], G20210A in prothrombin gene and C677T in methyltetrahydrofolate reductase [MTHFR] gene) have been associated with thrombosis and ocular involvement in BD with controversial results. AIM: To assess the effects of FVL, prothrombin and MTHFR SNP variants in patients with BD and thrombosis and ocular involvement by means of a systematic review and meta-analysis.
METHODS: We retrieved studies analyzing the genotype of the above-mentioned polymorphism among patients with BD. A meta-analysis was conducted in a random effects model and calculations of odds ratio (OR) and confidence intervals (CI) were done. Sensitivity analysis and tests for heterogeneity of the results were performed.
RESULTS: 27 previous studies analyzed the association of BD and thrombosis with the FVL, prothrombin and MTHFR polymorphisms. A significant association was found between the possession of the AA or GA genotypes of FVL polymorphism among patients with BD and the presence of any thrombosis (OR=2.51; 95% CI: 1.68, 3.74; P<0.00001). In addition, a significant association was found between the possession of the GA or AA genotypes and the presence of BD (OR=2.67; 95% CI: 1.93. 3.72; P<0.00001) when cases with BD and healthy controls were compared. This association was not found when studies from Turkey were excluded. No association was found between prothrombin and MTHFR SNPs and thrombosis in BD, and no association between any SNP and ocular involvement was shown either.
CONCLUSIONS: Factor V Leiden could be responsible for some thrombotic events in at least Turkish patients. However, this relationship has to be demonstrated from a pathogenic point of view.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23207285     DOI: 10.1016/j.autrev.2012.11.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  6 in total

Review 1.  Cardiovascular disease in patients with autoinflammatory syndromes.

Authors:  Rainer Hintenberger; Agnes Falkinger; Kathrin Danninger; Herwig Pieringer
Journal:  Rheumatol Int       Date:  2017-11-01       Impact factor: 2.631

2.  Association between Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Risk of Autoimmune Diseases: A Systematic Review and Meta-Analysis.

Authors:  Mao Lu; Ke Peng; Li Song; Li Luo; Peng Liang; Yundan Liang
Journal:  Dis Markers       Date:  2022-05-31       Impact factor: 3.464

3.  A rare case of Behçet disease with generalised myositis, cardiomyositis and necrotising fasciitis.

Authors:  Felix Ng; Fabian Joon Kiong Chiong; Russell Buchanan; Louise M Burrell
Journal:  BMJ Case Rep       Date:  2016-01-06

4.  Behçet's disease complicated with thrombosis: a report of 93 Chinese cases.

Authors:  Xiuhua Wu; Guohua Li; Xinxiang Huang; Li Wang; Wanli Liu; Yan Zhao; Wenjie Zheng
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

5.  Cerebral venous thrombosis revealing Behçet's disease in a Moroccan patient: A case report and literature review.

Authors:  Evelien Krumb; Chantal Lefebvre; André Peeters; Cédric Hermans
Journal:  SAGE Open Med Case Rep       Date:  2018-03-28

6.  Associations of Mitochondrial Deoxyribonucleic Acid Polymorphisms With Behçet's Disease in the Korean Population.

Authors:  Mihye Kwon; Su-Jin Yoo; In Seol Yoo; Jinhyun Kim; Seong Wook Kang; In Ah Choi; Mi-Kyoung Lim; Chung-Il Joung
Journal:  Arch Rheumatol       Date:  2019-01-28       Impact factor: 1.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.